Michael H Schiff, MD

Michael H Schiff, MD


Dr. Schiff is currently a Clinical Professor of Medicine in the Rheumatology Division at the University of Colorado School of Medicine in Denver. Board certified in Internal Medicine and Rheumatology, Dr. Schiff founded the Denver Arthritis Clinic and served as a Rheumatologist and Medical Director of the clinic’s Research Unit from 1976-2008.

He has received a number of Outstanding Clinical Faculty awards from the University of Colorado School of Medicine, including the Academic Publications Award, Career Achievement Award, and the Research Project Award. A principal investigator for more than 200 research projects, Dr. Schiff has published 50 peer-reviewed journal articles and 300 scientific abstracts.

Dr. Schiff is a fellow of the American College of Rheumatology, as well as a member of numerous regional and national medical societies. In addition, Dr. Schiff has served as a board member of the American College of Rheumatology Research Education Foundation and was vice president of the foundation from 2001 to 2002. A two-term president of the Colorado Society of Internal Medicine, Dr. Schiff’s primary interest has been in the use of DMARDS (disease-modifying antirheumatic drugs) and biologics for management of rheumatoid arthritis.

Dr. Schiff received his undergraduate training at the University of Chicago. He completed his medical degree at the State University of New York (SUNY) Downstate Medical Center. Dr. Schiff did his Internal Medicine residency at Albany Medical Center, Hospital of Union University School of Medicine and a fellowship in Rheumatology at SUNY Downstate Medical Center.


  1. M H Schiff, G R Burmester J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan:  Safety Analyses of Adalimumab (HUMIRA) in Global Clinical trials and US Postmarketing Surveillance of Patients with Rheumatoid Arthritis.  Ann Rheum Dis 2006;65 889-894.
  2. Well GA, Becker JC, Teng J, Dougados M, Schiff MH, Smolen JS, Aletaha D, Van Riel PL:  Validation of the Disease Activity Score 28 (DAS28) and EULAR response criteria based on CRP against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on ESR.  Ann Rheum Dis 2008 May 19.
  3. Schiff M, Keisermann M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M:  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.  Ann Rheum Dis 2008 Aug;67(8):1096-103. Epub 2007 Nov 29.
  4. Schiff M, Pritchard M, Huffstutter JE, Rodriguez-Valverde V et al. The 6−month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti−tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2008;68(11):1708-14.Schiff M, Bessette L:  Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis.  Clin Rheumatol. 2010 Jun;29(6):583-91.
  5. Schiff M, Bessette L:  Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis.  Clin Rheumatol. 2010 Jun;29(6):583-91.
  6. Schiff M: Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 201; 50(3):437-49.


Bookmark and Share